Shop Contact

Donaldson Announces Integrated Lentiviral Vector Manufacturing Platform Development

The first phase of a multi vector manufacturing platform solution

MINNEAPOLIS (May 8, 2024) — Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions, announced its Isolere Bio (Isolere) and Univercells Technologies businesses are developing an integrated upstream and downstream platform for viral vector manufacturing. The first phase will focus on lentivirus (LV) manufacturing, concentrating on improving recoveries with a scalable process while keeping the manufacturing footprint small.

"This manufacturing platform promises to establish a solution that accelerates process development timelines and reduces manufacturing complexity in the production of accessible cell and gene therapies worldwide."

Andrew Dahlgren, President, Donaldson Life Sciences

Univercells Technologies’ scale-X™ fixed-bed bioreactor has demonstrated high yields of infectious LV in perfusion mode. Isolere’s IsoTag™ LV affinity purification reagent enables non-chromatographic purification of LV vectors with high functional recoveries, high purity, decreased unit operations and reduced total processing time. The IsoTag LV reagent confers additional stabilizing properties to the LV vectors that may be advantageous when used in conjunction with the scale-X bioreactor.

"For the first phase of the manufacturing platform, we are starting with LV given the growing demand for this vector, as current infectious virus recoveries are low and the virus is unstable," said Kelli Luginbuhl, Isolere’s founder and general manager. "Achieving extended, low-shear perfusion culture in the scale-X bioreactor platform, together with the IsoTag LV’s in situ virus stabilization, will improve yields and lower costs.’"

Isolere’s pipeline of IsoTag reagents currently is focused on offering affinity purification solutions for adeno-associated virus (AAV), LV and positive-strand RNA viruses (ssRNA). These reagents combine tailored affinity ligands with liquid-liquid phase separation to sequester target biologics from complex solutions into large droplets. These droplets are concentrated and purified via tangential flow filtration using familiar equipment and off-the-shelf consumables.

Mathias Garny, Univercells Technologies’ general manager, said, "Scale-X technology is a demonstrated bioreactor platform for rapid process development and scale-up of virus manufacturing. The design of the scale-X fixed-bed enables extended low-shear perfusion operation as well as significant reductions in host cell proteins and host cell DNA. Unlike other bioreactors, both suspension and fixed-bed, this bioreactor is directly scalable from bench to commercial-scale. It is now in use at CDMOs worldwide for clinical trial manufacturing, and the first commercial product produced in the scale-X bioreactor will launch later this year."

"Donaldson is a new entrant into the bioprocessing space, having made selective and strategic acquisitions over the past three years," added Dahlgren. "A key element in our strategy is to acquire innovative companies such as Isolere and Univercells Technologies that together can make a significant difference in the manufacturing of complex biologics, increasing the availability of these life-changing medicines worldwide."

Interested in learning more about Donaldson? We can help.